Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Operating Leases for 7 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 20.2% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 20.2% year-over-year, with the annual reading at $2.6 million for FY2025, 20.2% down from the prior year.
  • Operating Leases hit $2.6 million in Q4 2025 for Rocket Pharmaceuticals, down from $2.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $3.7 million in Q1 2024 to a low of $200000.0 in Q1 2023.
  • Historically, Operating Leases has averaged $2.1 million across 5 years, with a median of $2.7 million in 2025.
  • Biggest five-year swings in Operating Leases: crashed 72.18% in 2023 and later skyrocketed 1757.0% in 2024.
  • Year by year, Operating Leases stood at $905000.0 in 2021, then rose by 20.22% to $1.1 million in 2022, then surged by 173.25% to $3.0 million in 2023, then increased by 9.59% to $3.3 million in 2024, then dropped by 20.2% to $2.6 million in 2025.
  • Business Quant data shows Operating Leases for RCKT at $2.6 million in Q4 2025, $2.8 million in Q3 2025, and $2.9 million in Q2 2025.